- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | On a roll, UCB picks up another rare disease FDA approval | ||
| 04.11. | Arcutis taps '90210' star power to spell out the needs of people with skin conditions | ||
| 04.11. | Insulet campaign takes aim at workplace challenges for people with diabetes | ||
| 04.11. | Teva recalls more than half-a-million bottles of blood pressure drug over potential carcinogens | ||
| 04.11. | Merck writes tale of 2 checks, bagging $700M from Blackstone and spending $150M to regain asset | ||
| 04.11. | Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3 | ||
| 03.11. | Pharma's corporate reputation dips among neurology patient groups, citing drug access challenges | ||
| 03.11. | Kimberly-Clark buys out Kenvue in $48.7B consumer health merger | ||
| 03.11. | Roche's Gazyva, on an autoimmune hot streak, looks to further its new foothold in lupus with phase 3 win | ||
| 03.11. | CDER chief George Tidmarsh resigns as deleted LinkedIn post prompts Aurinia lawsuit, FDA probe | ||
| 03.11. | Lilly's global manufacturing blitz rolls on with $3B plant in Netherlands, plans for 500 hires | ||
| 02.11. | Regulatory tracker: China approves first EGFR-targeted antibody-drug conjugate | ||
| 31.10. | AbbVie boosts revenue forecast by $400M thanks to booming sales of Skyrizi, Rinvoq | ||
| 31.10. | Facility Stability and Readiness: Optimized Design to Ensure Equivalency and Speed in Global Biopharmaceutical Manufacturing | ||
| 31.10. | Pediatrician group declines to back leucovorin for routine use against autism | ||
| 31.10. | Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales | ||
| 30.10. | Biogen boosts sales outlook on 'resilient' legacy MS franchise as new launches build momentum | ||
| 30.10. | CSL Seqirus strikes flu shot supply, production pact with Saudi Arabia | ||
| 30.10. | BMS' hyped schizophrenia launch Cobenfy delivers so-so launch year as execs map plan for future | ||
| 30.10. | As vaccines industry struggles, Merck's adult pneumococcal shot Capvaxive off to strong start | ||
| 30.10. | Lilly's Zepbound, Mounjaro show out with $10B quarter despite CVS formulary hitch | ||
| 30.10. | Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera | ||
| 29.10. | Amid Trump admin's drug pricing push, FDA aims to give biosimilars a boost | ||
| 29.10. | Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind' | ||
| 29.10. | Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival miss |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .